Welcome to our dedicated page for GRI Bio SEC filings (Ticker: GRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding a scientific journal. GRI Bio’s 200-page annual report is packed with clinical trial data, cash-burn tables, and complex immune-modulation science that investors need but rarely have time to dissect. If you have ever searched for “GRI Bio SEC filings explained simply” or wondered how to spot financing risk in the next “GRI Bio quarterly earnings report 10-Q filing,” you are not alone.
Stock Titan solves that problem. Our AI reviews every GRI Bio document the moment it hits EDGAR, turning dense disclosures into plain-language briefs. Whether it is a “GRI Bio 8-K material events explained” alert on a Phase 2 trial, or “GRI Bio insider trading Form 4 transactions” highlighting real-time executive stock moves, you see the key points first.
Here is how investors use the page:
- Scan AI-powered summaries of the latest 10-K to find R&D spend, clinical milestones, and cash runway—“GRI Bio annual report 10-K simplified.”
- Compare quarter-over-quarter trial expenses with instant context inside each 10-Q—our “GRI Bio earnings report filing analysis.”
- Set alerts for “GRI Bio executive stock transactions Form 4” to monitor confidence ahead of pivotal readouts.
- Review the proxy to understand “GRI Bio proxy statement executive compensation” without wading through legal jargon.
All filing types—10-K, 10-Q, 8-K, S-1, Form 4—update in real time. And because our platform explains immunotherapy terminology, you will finally feel comfortable “understanding GRI Bio SEC documents with AI.” Skip the scrolling; focus on decisions.
David Leslie Szekeres, a director of GRI Bio, Inc. (GRI), reported receipt of a stock option award covering 10,276 shares with an exercise price of $1.41 per share. The option was granted on 08/26/2025, has an expiration date in 2035, and 6,933 of the option shares vested immediately while the remaining 3,343 shares vest in four substantially equal quarterly installments, fully vesting on the first anniversary of the grant. Following the grant, the reporting person beneficially owns 10,276 option shares on a direct basis.
GRI Bio, Inc. director David Charles Baker received a stock option grant on 08/26/2025 allowing purchase of 5,994 shares of common stock at an exercise price of $1.41 per share. Of the total, 4,044 options vested immediately on the grant date; the remaining 1,950 options vest in four substantially equal quarterly installments and will be fully vested on the one-year anniversary of the grant. The options expire on 08/26/2035. Following the grant, Mr. Baker directly beneficially owns 5,994 underlying shares from the option award.
Roelof Rongen, a director of GRI Bio, Inc. (GRI), was granted a stock option on 08/26/2025 covering 5,994 shares with an exercise price of $1.41. The option has an expiration date of 08/26/2035 and the form reports 5,994 shares beneficially owned by the reporting person following the transaction. Of the options granted, 4,044 vested in full on the grant date and 1,950 will vest in four substantially equal quarterly installments, completing vesting on the first anniversary of the grant. The Form 4 was signed by an attorney-in-fact, Leanne Kelly, on 08/26/2025.
Vipin Chaturvedi, Chief Scientific Officer of GRI Bio, Inc. (GRI), reported receipt of a stock option award dated 08/26/2025 covering 11,854 options to purchase common stock at an exercise price of $1.41 per share. Following the reported transaction, he beneficially owns 11,854 options directly. The grant vests in two parts: 7,424 options vested in full on the grant date, while 4,430 options will vest in 12 substantially equal quarterly installments and become fully vested on the third anniversary of the grant. The option expiration date is 08/26/2035. The filing was signed by an attorney-in-fact on behalf of the reporting person.
Camilla V. Simpson, a director of GRI Bio, acquired a stock option covering 5,994 shares of the issuer's common stock with an exercise price of $1.41. The option grant is exercisable beginning 08/26/2025 and expires 08/26/2035. Of the 5,994 underlying shares, 4,044 vested immediately and 1,950 vest in four substantially equal quarterly installments so the option is fully vested on the first anniversary of the grant. Following the reported transaction, Ms. Simpson beneficially owns 5,994 shares and holds them in a direct ownership form. The Form 4 was submitted by one reporting person and signed by an attorney-in-fact.
GRI Bio, Inc. reported a Form 4 showing that Chief Financial Officer Leanne Kelly was granted a stock option on 08/26/2025 to purchase 11,854 shares of common stock at an exercise price of $1.41 per share. The option becomes exercisable immediately for 7,424 shares while the remaining 4,430 shares vest in 12 substantially equal quarterly installments, fully vesting on the third anniversary of the grant. The option expires on 08/26/2035. Following the transaction, Ms. Kelly beneficially owns 11,854 options directly.
GRI Bio, Inc. director Camilla V. Simpson was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share. The option appears in Table II as a derivative security with an expiration date of 08/13/2035. The filing states the option vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date. The reporting person is shown as a director and the Form 4 was signed by an attorney-in-fact on 08/14/2025.
GRI Bio, Inc. director David Charles Baker was granted a stock option on 08/13/2025 to buy 4,527 shares of common stock at an exercise price of $1.30 per share. The option is exercisable with a vesting schedule of four equal quarterly installments and becomes fully vested on the first anniversary of the grant. The option expires on 08/13/2035. Following the grant, Mr. Baker beneficially owns 4,527 derivative shares on a direct basis. The Form 4 was signed by an attorney-in-fact, Leanne Kelly, on 08/14/2025.
Roelof Rongen, a director of GRI Bio, Inc. (GRI), was granted a stock option to buy 4,527 shares of common stock at an exercise price of $1.30 per share on 08/13/2025. The option vests in four equal quarterly installments and is fully vested on the first anniversary of the grant date, with an exercise/expiration schedule showing exercisability beginning 08/13/2025 and an expiration date of 08/13/2035. Following the grant, Mr. Rongen directly beneficially owns 4,527 underlying shares/options. The Form 4 was filed as a single reporting person filing and signed by an attorney-in-fact on 08/14/2025.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
